The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of
NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care
gemcitabine/nab-paclitaxel. Furthermore, we propose that the NAPOLI regimen and
seq-NAPOLI-FOLFOX display favourable safety profiles and allow for longer first line
treatment and higher rate of transition into the second line setting.